Literature DB >> 32306783

A conjunctive lipidomic approach reveals plasma ethanolamine plasmalogens and fatty acids as early diagnostic biomarkers for colorectal cancer patients.

Tong Liu1,2,3,4, Zhirong Tan1,2,3,4, Jing Yu1,2,3,4, Peng Feng1,2,3,4, Jiwei Guo1,2,3,4, Wenhui Meng1,2,3,4, Yao Chen1,2,3,4, Tai Rao1,2,3,4, Zhaoqian Liu1,2,3,4, Jingbo Peng1,2,3,4.   

Abstract

Background: Colorectal cancer (CRC) represents a third leading cause of cancer-related death worldwide. The reliable diagnostic biomarkers for detecting CRC at early stage is critical for decreasing the mortality.Method: A conjunctive lipidomic approach was employed to investigate the differences in plasma lipid profiles of CRC patients (n = 101) and healthy volunteers (n = 52). Based on UHPLC-Q-TOF MS and UHPLC-QQQ MS platforms, a total of 235 lipids were structurally detected. Multivariate data analysis was conducted including partial least squared discriminant analysis (PLS-DA), fold change performance and Mann-Whitney U test.
Results: A total of 11 lipid species, including 1 Glycerophosphoethanolamine (PE), 3 ethanolamine plasmalogens (PlsEtn), 1 plasmanyl glycerophosphatidylethanolamine (PE-O), 3 fatty acids (FFA), 1 Fatty acid ester of hydroxyl fatty acid (FAHFA), and 2 Diacylglycerophosphates (PA) were identified to distinguish the CRC patients at early stage from healthy controls. In addition, these potential lipid biomarkers achieved an estimated AUC=0.981 in a validation set for univariate ROC analysis.
Conclusion: By combining Q-TOF MS and QQQ MS analysis, the 11 lipids exhibited good performance in differentiating early-stage CRC and healthy control. This study also demonstrated that the lipidomics is a powerful tool in discovering new potential biomarkers for cancer diagnosis.

Entities:  

Keywords:  Q-TOF MS; QQQ MS; colorectal cancer; diagnostic biomarkers; lipidomics

Year:  2020        PMID: 32306783     DOI: 10.1080/14789450.2020.1757443

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  8 in total

1.  Applications of Lipidomics in Tumor Diagnosis and Therapy.

Authors:  Yuping Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Baseline Elevations of Leukotriene Metabolites and Altered Plasmalogens Are Prognostic Biomarkers of Plaque Progression in Systemic Lupus Erythematosus.

Authors:  Sahar Baig; Kamala Vanarsa; Huihua Ding; Anto Sam Crosslee Louis Sam Titus; Maureen McMahon; Chandra Mohan
Journal:  Front Cardiovasc Med       Date:  2022-05-16

Review 3.  Tricky Isomers-The Evolution of Analytical Strategies to Characterize Plasmalogens and Plasmanyl Ether Lipids.

Authors:  Jakob Koch; Katrin Watschinger; Ernst R Werner; Markus A Keller
Journal:  Front Cell Dev Biol       Date:  2022-04-27

4.  Lipidomic Signatures for Colorectal Cancer Diagnosis and Progression Using UPLC-QTOF-ESI+MS.

Authors:  Claudiu Răchieriu; Dan Tudor Eniu; Emil Moiş; Florin Graur; Carmen Socaciu; Mihai Adrian Socaciu; Nadim Al Hajjar
Journal:  Biomolecules       Date:  2021-03-11

5.  Serum Untargeted UHPLC-HRMS-Based Lipidomics to Discover the Potential Biomarker of Colorectal Advanced Adenoma.

Authors:  Yifan Zhu; Lisheng Wang; Yanying Nong; Yunxiao Liang; Zongsheng Huang; Pingchuan Zhu; Qisong Zhang
Journal:  Cancer Manag Res       Date:  2021-11-26       Impact factor: 3.989

Review 6.  Reprogrammed Lipid Metabolism and the Lipid-Associated Hallmarks of Colorectal Cancer.

Authors:  Timothy Salita; Yepy H Rustam; Dmitri Mouradov; Oliver M Sieber; Gavin E Reid
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

7.  UHPLC-HRMS-based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer.

Authors:  Hongwei Chen; Jiahao Zhang; Hailin Zhou; Yifan Zhu; Yunxiao Liang; Pingchuan Zhu; Qisong Zhang
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

8.  Serum untargeted lipidomics by UHPLC-ESI-HRMS aids the biomarker discovery of colorectal adenoma.

Authors:  Hailin Zhou; Yanying Nong; Yifan Zhu; Yunxiao Liang; Jiahao Zhang; Hongwei Chen; Pingchuan Zhu; Qisong Zhang
Journal:  BMC Cancer       Date:  2022-03-24       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.